Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways

Cancer Letters

Volumn 355, Issue 2, 2014, Pages 232-241

  Zhao, Zhizheng ^a,b   Fan, Huiting ^a,b   Higgins, Tim ^a   Qi, Jia ^c   Haines, Diana ^d   Trivett, Anna ^a   Oppenheim, Joost J ^a   Wei, Hou ^b   Li, Jie ^b   Lin, Hongsheng ^b   Howard, O M Zack ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

ERK; Fufang Kushen injection; Hyperalgesia; Sarcoma; TRPV1

Indexed keywords

ANTINEOPLASTIC AGENT; CAPSAICIN; CHINESE DRUG; CXCL1 CHEMOKINE; FUFANG KUSHEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAD; PROTEIN KINASE B; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; CYTOKINE; FUFANGKUSHEN; HERBACEOUS AGENT; TRPV1 PROTEIN, MOUSE; VANILLOID RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PAIN; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; EMBRYO; HUMAN; HUMAN CELL; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROPATHIC PAIN; NEWBORN; NONHUMAN; PROTEIN PHOSPHORYLATION; SARCOMA 180; SIGNAL TRANSDUCTION; TUMOR REGRESSION; ANIMAL; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; ENZYMOLOGY; FEMALE; METABOLISM; PHOSPHORYLATION; SARCOMA; TUMOR CELL LINE;

ANIMALS; CAPSAICIN; CELL LINE, TUMOR; CYTOKINES; DRUGS, CHINESE HERBAL; FEMALE; HYPERALGESIA; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SARCOMA; TRPV CATION CHANNELS;

EID: 84908216805     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.08.037     Document Type: Article

References (55)

1. Argyriou A.A., Kyritsis A.P., Makatsoris T., Kalofonos H.P. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag. Res 2014, 6:135-147.
2. Modesto-Lowe V., Girard L., Chaplin M. Cancer pain in the opioid-addicted patient: can we treat it right?. J. Opioid Manag 2012, 8:167-175.
3. Ahlbeck K. Opioids: a two-faced Janus. Curr. Med. Res. Opin 2011, 27:439-448.
4. Brant J.M. The global experience of cancer pain. Asian Pac. J. Cancer Prev 2010, 11(Suppl. 1):7-12.
5. Thapa D., Rastogi V., Ahuja V. Cancer pain management-current status. J. Anaesthesiol. Clin. Pharmacol 2011, 27:162-168.
6. Gradl G., Gaida S., Gierer P., Mittlmeier T., Vollmar B. In vivo evidence for apoptosis, but not inflammation in the hindlimb muscle of neuropathic rats. Pain 2004, 112:121-130.
7. Liou J.T., Liu F.C., Mao C.C., Lai Y.S., Day Y.J. Inflammation confers dual effects on nociceptive processing in chronic neuropathic pain model. Anesthesiology 2011, 114:660-672.
8. Qi J., Buzas K., Fan H., Cohen J.I., Wang K., Mont E., et al. Painful pathways induced by TLR stimulation of dorsal root ganglion neurons. J. Immunol 2011, 186:6417-6426.
9. Lee H.J., Lee J.H., Lee E.O., Lee H.J., Kim K.H., Lee K.S., et al. Substance P and beta endorphin mediate electroacupuncture induced analgesic activity in mouse cancer pain model. Acupunct. Electrother Res 2009, 34:27-40.
10. Shimoyama M., Tanaka K., Hasue F., Shimoyama N. A mouse model of neuropathic cancer pain. Pain 2002, 99:167-174.
11. Asai H., Ozaki N., Shinoda M., Nagamine K., Tohnai I., Ueda M., et al. Heat and mechanical hyperalgesia in mice model of cancer pain. Pain 2005, 117:19-29.
12. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824.
13. Karai L., Brown D.C., Mannes A.J., Connelly S.T., Brown J., Gandal M., et al. Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control. J. Clin. Invest 2004, 113:1344-1352.
14. Xu Q., Garraway S.M., Weyerbacher A.R., Shin S.J., Inturrisi C.E. Activation of the neuronal extracellular signal-regulated kinase 2 in the spinal cord dorsal horn is required for complete Freund's adjuvant-induced pain hypersensitivity. J. Neurosci 2008, 28:14087-14096.
15. Guo S.W., Liu M.G., Long Y.L., Ren L.Y., Lu Z.M., Yu H.Y., et al. Region- or state-related differences in expression and activation of extracellular signal-regulated kinases (ERKs) in naive and pain-experiencing rats. BMC Neurosci 2007, 8:53.
16. Ji R.R., Baba H., Brenner G.J., Woolf C.J. Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat. Neurosci 1999, 2:1114-1119.
17. Gao Y.J., Ji R.R. c-Fos and pERK, which is a better marker for neuronal activation and central sensitization after noxious stimulation and tissue injury?. Open Pain J. 2009, 2:11-17.
18. Han Y., Li Y., Xiao X., Liu J., Meng X.L., Liu F.Y., et al. Formaldehyde up-regulates TRPV1 through MAPK and PI3K signaling pathways in a rat model of bone cancer pain. Neurosci. Bull 2012, 28:165-172.
19. Homma Y., Nomiya A., Tagaya M., Oyama T., Takagaki K., Nishimatsu H., et al. Increased mRNA expression of genes involved in pronociceptive inflammatory reactions in bladder tissue of interstitial cystitis. J. Urol 2013, 190:1925-1931.
20. Gui Q., Xu C., Zhuang L., Xia S., Chen Y., Peng P., et al. A new rat model of bone cancer pain produced by rat breast cancer cells implantation of the shaft of femur at the third trochanter level. Cancer Biol. Ther 2013, 14:193-199.
21. Lautner M.A., Ruparel S.B., Patil M.J., Hargreaves K.M. In vitro sarcoma cells release a lipophilic substance that activates the pain transduction system via TRPV1. Ann. Surg. Oncol 2011, 18:866-871.
22. Zhang N., Inan S., Cowan A., Sun R., Wang J.M., Rogers T.J., et al. A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:4536-4541.
23. Xu W., Lin H., Zhang Y., Chen X., Hua B., Hou W., et al. Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/beta-catenin pathway. J. Exp. Clin. Cancer Res 2011, 30:103.
24. Fan C.-X., Lin C.-L., Liang L., Zhao Y.-Y., Liu J., Cui J., et al. Enhancing effect of compound Kusheng injection in combination with chemotherapy for patients with advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2010, 32:294-297.
25. Berghe W.V., De Naeyer A., Dijsselbloem N., David J.-P., De Keukeleire D., Haegeman G. Attenuation of ERK/RSK2-driven NFkappaB gene expression and cancer cell proliferation by kurarinone, a lavandulyl flavanone isolated from Sophora flavescens ait. roots. Endocr. Metab. Immune Disord. Drug Targets 2011, 11:247-261.
26. Dong X.-Q., Du Q., Yu W.-H., Zhang Z.-Y., Zhu Q., Che Z.-H., et al. Anti-inflammatory effects of oxymatrine through inhibition of nuclear factor-kappa B and mitogen-activated protein kinase activation in lipopolysaccharide-induced BV2 microglia cells. Iran. J. Pharm. Res 2013, 12:165-174.
27. Han J.-M., Jin Y.-Y., Kim H.Y., Park K.H., Lee W.S., Jeong T.-S. Lavandulyl flavonoids from sophora flaveseens suppress lipopolysaccharide-induced activation of nuclear factor-kappa B and mitogen-activated protein kinases in RAW264.7 cells. Biol. Pharm. Bull 2010, 33:1019-1023.
28. Kim B.-H., Won C., Lee Y.-H., Choi J.S., Noh K.H., Han S., et al. Sophoraflavanone G induces apoptosis of human cancer cells by targeting upstream signals of STATs. Biochem. Pharmacol 2013, 86:950-959.
29. Li T., Wong V.K.W., Yi X.Q., Wong Y.F., Zhou H., Liu L. Matrine induces cell anergy in human Jurkat T cells through modulation of mitogen-activated protein kinases and nuclear factor of activated T-cells signaling with concomitant up-regulation of anergy-associated genes expression. Biol. Pharm. Bull 2010, 33:40-46.
30. Liu X.S., Jiang J. Enhancement of imatinib-induced apoptosis by matrine in bcr/abl-positive leukemia K562 cells. Pharm. Biol 2006, 44:287-291.
31. Liu X.S., Jiang J.K., Jiao X.Y., Wu Y.E., Lin J.H. Matrine-induced apoptosis in leukemia U937 cells: involvement of caspases activation and MAPK-independent pathways. Planta Med 2006, 72:501-506.
32. Chen Y., Willcockson H.H., Valtschanoff J.G. Vanilloid receptor TRPV1-mediated phosphorylation of ERK in murine adjuvant arthritis. Osteoarthritis Cartilage 2009, 17:244-251.
33. Shevach E.M. Labeling cells in microtiter plates for determination of [3H]thymidine uptake. Curr. Protoc. Immunol 2001, 21. Appendix 3-Appendix 3D.
34. Berghmans N., Nuyts A., Uyttenhove C., Van Snick J., Opdenakker G., Heremans H. Interferon-gamma orchestrates the number and function of Th17 cells in experimental autoimmune encephalomyelitis. J. Interferon Cytokine Res 2011, 31:575-587.
35. Hayakawa J., Ohmichi M., Kurachi H., Kanda Y., Hisamoto K., Nishio Y., et al. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 2000, 60:5988-5994.
36. Liu J., Xue M., Huang X., Wang S., Jiang Z., Zhang L. [Pharmacokinetic of four alkaloids of Yanshu injection in Beagel dogs]. Zhongguo Zhong Yao Za Zhi 2012, 37:1845-1849.
37. Li Z.W., Li G.F., Zhang J.H. [Pharmacokinetics and bioavailability of sustained-release tablets of matrine in dogs]. Zhong Yao Cai 2010, 33:1293-1296.
38. Wang Y., Ma Y., Li X., Qin F., Lu X., Li F. Simultaneous determination and pharmacokinetic study of oxymatrine and matrine in beagle dog plasma after oral administration of Kushen formula granule, oxymatrine and matrine by LC-MS/MS. Biomed. Chromatogr 2007, 21:876-882.
39. Danial N.N. BAD: undertaker by night, candyman by day. Oncogene 2008, 27(Suppl. 1):S53-S70.
40. Wang L.N., Yao M., Yang J.P., Peng J., Peng Y., Li C.F., et al. Cancer-induced bone pain sequentially activates the ERK/MAPK pathway in different cell types in the rat spinal cord. Mol. Pain 2011, 7:48.
41. Gimenez-Cassina A., Martinez-Francois J.R., Fisher J.K., Szlyk B., Polak K., Wiwczar J., et al. BAD-dependent regulation of fuel metabolism and K(ATP) channel activity confers resistance to epileptic seizures. Neuron 2012, 74:719-730.
42. Cai Y., Chen T., Xu Q. Astilbin suppresses collagen-induced arthritis via the dysfunction of lymphocytes. Inflamm. Res 2003, 52:334-340.
43. Xu Q., Yuan K.W., Lu J.F., Wang R., Wu F.H. A new strategy for regulating the immunological liver injury - effectiveness of DTH-inhibiting agents on dth-induced liver injury to picryl chloride. Pharmacol. Res 1997, 36:401-409.
44. Liu G., Dong J., Wang H., Hashi Y., Chen S. Characterization of alkaloids in Sophora flavescens Ait. by high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. J. Pharm. Biomed. Anal 2011, 54:1065-1072.
45. Lin Z., Huang C.F., Liu X.S., Jiang J. In vitro anti-tumour activities of quinolizidine alkaloids derived from Sophora flavescens Ait. Basic Clin. Pharmacol. Toxicol 2011, 108:304-309.
46. Guenther M.K., Graab U., Fulda S. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. Cancer Lett 2013, 337:200-209.
47. Sun Q., Ma W., Gao Y., Zheng W., Zhang B., Peng Y. Meta-analysis: therapeutic effect of transcatheter arterial chemoembolization combined with compound kushen injection in hepatocellular carcinoma. Afr. J. Tradit. Complement. Altern. Med 2012, 9:178-188.
48. China Food and Drug Adminstration Notice on GMP certification (for injections, radioactive drugs and biologicals defined by drug regulatory department under the State Council). GMP Certification 2013.
49. Forscher C., Mita M., Figlin R. Targeted therapy for sarcomas. Biologics 2014, 8:91-105.
50. Melemedjian O.K., Khoutorsky A., Sorge R.E., Yan J., Asiedu M.N., Valdez A., et al. mTORC1 inhibition induces pain via IRS-1-dependent feedback activation of ERK. Pain 2013, 154:1080-1091.
51. Pignochino Y., Grignani G., Cavalloni G., Motta M., Tapparo M., Bruno S., et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol. Cancer 2009, 8:118.
52. Weil A., Moore S.E., Waite N.J., Randall A., Gunthorpe M.J. Conservation of functional and pharmacological properties in the distantly related temperature sensors TRVP1 and TRPM8. Mol. Pharmacol 2005, 68:518-527.
53. Ferrer-Montiel A., Fernandez-Carvajal A., Planells-Cases R., Fernandez-Ballester G., Gonzalez-Ros J.M., Messeguer A., et al. Advances in modulating thermosensory TRP channels. Expert Opin. Ther. Pat 2012, 22:999-1017.
54. Honore P., Chandran P., Hernandez G., Gauvin D.M., Mikusa J.P., Zhong C., et al. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. Pain 2009, 142:27-35.
55. Finley M.J., Happel C.M., Kaminsky D.E., Rogers T.J. Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cell. Immunol 2008, 252:146-154.